Due to lack of power, the results did not allow for a conclusion to be drawn. Overall, moderate-quality evidence indicated that tiotropium + LABA/ICS vs. tiotropium + placebo decreased hospital ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Two strategies are commonly used as maintenance treatment for patients with moderate or severe chronic obstructive pulmonary disease (COPD): (1) an inhaled corticosteroid + long-acting beta-agonist ...

Patients with chronic obstructive pulmonary disease (COPD) experienced significantly fewer acute exacerbations when a long-acting muscarinic antagonist (LAMA) was added to a long-acting beta agonist ...

Clinical guidelines currently recommend LABA/LAMA therapy as an alternative to LABA/ICS but evidence on the comparative effectiveness of these combination therapies for COPD is limited. Treatment with ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

Among patients with mild asthma, as-needed use of a fixed-dose inhaler combining budesonide and formoterol (Symbicort) proved effective for preventing exacerbations and loss of lung function, but the ...

Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA:- What is the clinical and cost effectiveness of offering additional maintenance therapy ...